Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
Needham has downgraded NeoGenomics Inc (NASDAQ:NEO) from Buy to Hold, citing that NEO’s turnaround will likely take several years and believes…